Genomic and transcriptomic approaches reveal disease-specific risk genes (e.g., TREM2 in Alzheimer’s disease, ATXN2 in ALS) and biomarkers, enabling more precise diagnosis and personalized medicine [37]. The gene discussed is TREM2; the disease is early-onset autosomal dominant Alzheimer disease.